Related Experiment Video

Updated: May 21, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With

Rami S Komrokji1, Muhammad Ammad-Ud-Din1, Najla H Al Ali1

  • 1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.

Clinical Lymphoma, Myeloma & Leukemia
|March 20, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
AnemiaLower risk MDSRed blood cell transfuion dependencyResponse to treatmentmyelodysplastic neoplasms

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Related Experiment Videos

Last Updated: May 21, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

268
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
268
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

Articles linked to this work by shared authors, journal, and citation graph.

VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.

Blood advances·2026

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.

Cancer·2026

At the heart of unmet need: TP53 myeloid neoplasms.

The Lancet. Haematology·2026

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.

Journal for immunotherapy of cancer·2026

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Blood·2026

Asciminib After Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia: A Multicenter Real-World Experience.

Clinical lymphoma, myeloma & leukemia·2026

N-AVD or BrECADD for Advanced-Stage Classical Hodgkin Lymphoma: Choosing the Right Treatment for the Right Patient.

Clinical lymphoma, myeloma & leukemia·2026

Twenty-Five Years of CML Therapy in India: A Model for Precision Oncology in a Resource-Constrained Setting.

Clinical lymphoma, myeloma & leukemia·2026

Cardiovascular Toxicities of Contemporary Cancer Immunotherapies: A Narrative Review of Immune Checkpoint Inhibitors, Bispecific T-Cell Engagers, and CAR-T Cell Therapies.

Clinical lymphoma, myeloma & leukemia·2026

IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026

SOHO State of the Art Updates and Next Questions | The Evolving AML Treatment Paradigm.

Clinical lymphoma, myeloma & leukemia·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us